Om

SCYNEXIS, Inc. Common Stock represents the equity of SCYNEXIS, Inc., a biotechnology company focused on developing therapies for difficult-to-treat and drug-resistant fungal infections as well as certain severe rare diseases. The company markets BREXAFEMME for vulvovaginal candidiasis and recurrent vulvovaginal candidiasis, while also advancing investigational candidates such as ibrexafungerp and SCY-247 for broader antifungal and infectious disease applications. SCYNEXIS works across drug development, commercialization, and collaborative partnerships to support the treatment and prevention of serious infections with limited options. Headquartered in Jersey City, New Jersey, the company operates in the specialty pharmaceuticals segment of the healthcare market and serves as a focused biotechnology platform centered on anti-infective innovation.

Markedsdata leveret af TwelveData og Morningstar

Aktiemarkedet kan gå både op og ned. Selvom investeringer i aktier historisk set har givet investorer et positivt afkast på langt sigt, er der ingen garanti for fremtidige afkast. Der er derfor en risiko for, at du ikke får de investerede penge tilbage.

INVESTER I SCYNEXIS MED ENDAVU: Køb SCYNEXIS ($135) aktier gennem Endavu’s investeringsplatform. Hos Endavu kan du købe og sælge aktier i SCYNEXIS, og handle med aktier, fraktionaler, ETF'er og andre finansielle instrumenter. Endavu tilbyder handel uden kurtage på amerikanske aktier. Endavu tilbyder lav kurtage på tværs af aktier. Handl med over 30.000 forskellige aktier og udenfor markedsåbningstider.